UniProt ID | ENC1_HUMAN | |
---|---|---|
UniProt AC | O14682 | |
Protein Name | Ectoderm-neural cortex protein 1 | |
Gene Name | ENC1 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 589 | |
Subcellular Localization | Nucleus matrix . Cytoplasm . Cytoplasm, cytoskeleton . | |
Protein Description | Actin-binding protein involved in the regulation of neuronal process formation and in differentiation of neural crest cells. Down-regulates transcription factor NF2L2/NRF2 by decreasing the rate of protein synthesis and not via a ubiquitin-mediated proteasomal degradation mechanism.. | |
Protein Sequence | MSVSVHENRKSRASSGSINIYLFHKSSYADSVLTHLNLLRQQRLFTDVLLHAGNRTFPCHRAVLAACSRYFEAMFSGGLKESQDSEVNFDNSIHPEVLELLLDYAYSSRVIINEENAESLLEAGDMLEFQDIRDACAEFLEKNLHPTNCLGMLLLSDAHQCTKLYELSWRMCLSNFQTIRKNEDFLQLPQDMVVQLLSSEELETEDERLVYESAINWISYDLKKRYCYLPELLQTVRLALLPAIYLMENVAMEELITKQRKSKEIVEEAIRCKLKILQNDGVVTSLCARPRKTGHALFLLGGQTFMCDKLYLVDQKAKEIIPKADIPSPRKEFSACAIGCKVYITGGRGSENGVSKDVWVYDTLHEEWSKAAPMLVARFGHGSAELKHCLYVVGGHTAATGCLPASPSVSLKQVEHYDPTINKWTMVAPLREGVSNAAVVSAKLKLFAFGGTSVSHDKLPKVQCYDQCENRWTVPATCPQPWRYTAAAVLGNQIFIMGGDTEFSACSAYKFNSETYQWTKVGDVTAKRMSCHAVASGNKLYVVGGYFGIQRCKTLDCYDPTLDVWNSITTVPYSLIPTAFVSTWKHLPS | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Phosphorylation | ------MSVSVHENR ------CCCCCCCCC | 24.09 | 22496350 | |
11 | Phosphorylation | SVHENRKSRASSGSI CCCCCCCHHCCCCCE | 29.82 | 29523821 | |
14 | Phosphorylation | ENRKSRASSGSINIY CCCCHHCCCCCEEEE | 33.84 | 22777824 | |
15 | Phosphorylation | NRKSRASSGSINIYL CCCHHCCCCCEEEEE | 35.26 | 22777824 | |
17 | Phosphorylation | KSRASSGSINIYLFH CHHCCCCCEEEEEEE | 17.89 | 29523821 | |
26 | Phosphorylation | NIYLFHKSSYADSVL EEEEEECHHHHHHHH | 21.73 | 28258704 | |
27 | Phosphorylation | IYLFHKSSYADSVLT EEEEECHHHHHHHHH | 29.19 | 28258704 | |
28 | Phosphorylation | YLFHKSSYADSVLTH EEEECHHHHHHHHHH | 22.86 | 28258704 | |
31 | Phosphorylation | HKSSYADSVLTHLNL ECHHHHHHHHHHHHH | 15.74 | 28258704 | |
34 | Phosphorylation | SYADSVLTHLNLLRQ HHHHHHHHHHHHHHH | 23.35 | 28258704 | |
46 | Phosphorylation | LRQQRLFTDVLLHAG HHHHHHHHHHHHCCC | 29.77 | 24719451 | |
70 | Phosphorylation | VLAACSRYFEAMFSG HHHHHHHHHHHHHCC | 6.89 | - | |
168 | Phosphorylation | CTKLYELSWRMCLSN HHHHHHHHHHHHHHC | 10.74 | 24719451 | |
213 | Phosphorylation | DERLVYESAINWISY HHHHHHHHHHHHHCC | 19.43 | 26270265 | |
219 | Phosphorylation | ESAINWISYDLKKRY HHHHHHHCCCHHHCC | 12.28 | 26270265 | |
220 | Phosphorylation | SAINWISYDLKKRYC HHHHHHCCCHHHCCC | 19.03 | 26270265 | |
245 | Phosphorylation | LALLPAIYLMENVAM HHHHHHHHHHHHHHH | 11.34 | 22817900 | |
263 | Ubiquitination | ITKQRKSKEIVEEAI HHHHHHCHHHHHHHH | 55.27 | - | |
285 | Phosphorylation | QNDGVVTSLCARPRK CCCCCEEEEECCCCC | 15.16 | 24719451 | |
304 | Phosphorylation | LFLLGGQTFMCDKLY EEEECCCEECCCEEE | 19.33 | 19690332 | |
316 | Ubiquitination | KLYLVDQKAKEIIPK EEEECCHHHHHHCCC | 57.89 | - | |
318 | Ubiquitination | YLVDQKAKEIIPKAD EECCHHHHHHCCCCC | 57.38 | - | |
331 | Ubiquitination | ADIPSPRKEFSACAI CCCCCCCHHHCCCEE | 67.50 | - | |
406 | Phosphorylation | ATGCLPASPSVSLKQ CCCCCCCCCCCCHHH | 18.77 | 30576142 | |
408 | Phosphorylation | GCLPASPSVSLKQVE CCCCCCCCCCHHHCE | 23.11 | 22617229 | |
410 | Phosphorylation | LPASPSVSLKQVEHY CCCCCCCCHHHCEEC | 33.90 | 26434776 | |
417 | Phosphorylation | SLKQVEHYDPTINKW CHHHCEECCCCCCEE | 15.31 | - | |
423 | Ubiquitination | HYDPTINKWTMVAPL ECCCCCCEEEEEEEC | 39.94 | - | |
435 | Phosphorylation | APLREGVSNAAVVSA EECCCCCCHHHHHHH | 31.44 | 17924679 | |
441 | Phosphorylation | VSNAAVVSAKLKLFA CCHHHHHHHEEEEEE | 17.06 | 17924679 | |
443 | Ubiquitination | NAAVVSAKLKLFAFG HHHHHHHEEEEEEEC | 38.35 | 21906983 | |
452 | Phosphorylation | KLFAFGGTSVSHDKL EEEEECCCCCCCCCC | 26.74 | - | |
453 | Phosphorylation | LFAFGGTSVSHDKLP EEEECCCCCCCCCCC | 25.54 | - | |
455 | Phosphorylation | AFGGTSVSHDKLPKV EECCCCCCCCCCCCC | 26.24 | - | |
520 | Ubiquitination | SETYQWTKVGDVTAK CCEEEEEEECCEEEC | 41.06 | 21906983 | |
527 | Ubiquitination | KVGDVTAKRMSCHAV EECCEEECCCEEEEE | 38.99 | 21906983 | |
530 | Phosphorylation | DVTAKRMSCHAVASG CEEECCCEEEEEEEC | 13.54 | 24425749 | |
541 | Phosphorylation | VASGNKLYVVGGYFG EEECCEEEEECCEEC | 8.49 | 24425749 | |
569 | Phosphorylation | LDVWNSITTVPYSLI CCCHHCCCCCCHHHC | 22.89 | 18452278 | |
570 | Phosphorylation | DVWNSITTVPYSLIP CCHHCCCCCCHHHCC | 20.15 | 18452278 | |
573 | Phosphorylation | NSITTVPYSLIPTAF HCCCCCCHHHCCCHH | 16.27 | 18452278 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of ENC1_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of ENC1_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of ENC1_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
CUL3_HUMAN | CUL3 | physical | 15983046 | |
RBX1_HUMAN | RBX1 | physical | 15983046 | |
ACTB_HUMAN | ACTB | physical | 15208678 | |
NF2L2_HUMAN | NFE2L2 | physical | 20511222 | |
ENC1_HUMAN | ENC1 | physical | 16306221 | |
ENC1_HUMAN | ENC1 | physical | 15983046 | |
SQSTM_HUMAN | SQSTM1 | physical | 26637326 | |
KLH25_HUMAN | KLHL25 | physical | 28514442 | |
NUDC3_HUMAN | NUDCD3 | physical | 28514442 | |
PLIN5_HUMAN | PLIN5 | physical | 28514442 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Improved titanium dioxide enrichment of phosphopeptides from HeLacells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra."; Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; J. Proteome Res. 6:4150-4162(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-435 AND SER-441, ANDMASS SPECTROMETRY. |